Latest filing published 05 Sept 2024 for Karyopharm Therapeutics Inc., €4,592. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
All filings by Michael Mason on record concern Karyopharm Therapeutics Inc., in the capacity of finance chief. We count 16 filings; the first trade dates from 1 June 2021 and the latest from 4 September 2024.
The open-market record consists of 11 sales worth €113k, with no purchase. Outside the open market, there are 5 share grants. 2024 to date brings no purchases and 5 sales.
The record was last updated on 5 September 2024 with an open-market sale (€4,592) in Karyopharm Therapeutics Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
16 of 16 declarations